Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction
- PMID: 19200056
- DOI: 10.1042/CS20080390
Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction
Abstract
Left ventricular diastolic dysfunction represents a frequent clinical condition and is associated with increased cardiovascular morbidity and mortality. Diastolic dysfunction is the most common cause of HF-PSF (heart failure with preserved ejection fraction). Therefore it becomes important to understand the pathophysiological mechanisms underlying diastolic dysfunction, as well as the effective therapeutic strategies able to antagonize its development and progression. Among the complex pathophysiological factors that may contribute to the development of diastolic dysfunction, the RAAS (renin-angiotensin-aldosterone system) has been shown to play a significant role. Paracrine and autocrine signals of the RAAS promote structural and functional changes in the heart largely linked to increased myocardial fibrosis. Enhanced and dysregulated activity of the RAAS also contributes to the development of volume overload and vasoconstriction with subsequent increases in left ventricular diastolic filling pressures and a higher susceptibility of developing CHF (congestive heart failure). More recently, it has also been suggested that the RAAS may play a role in triggering myocardial and vascular inflammation through the activation of different cell types and the secretion of cytokines and chemokines. RAAS-induced myocardial inflammation leads to perivascular myocardial fibrosis and to the development or progression of diastolic dysfunction. For these reasons pharmacological blockade of the RAAS has been proposed as a rational approach for the treatment of diastolic dysfunction. In fact, ACEIs (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers) and AAs (aldosterone antagonists) have been demonstrated to delay the development and progression from pre-clinical diastolic dysfunction towards CHF, as well as to reduce the morbidity and mortality associated with this condition.
Similar articles
-
[Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].Praxis (Bern 1994). 1997 Apr 2;86(14):566-74. Praxis (Bern 1994). 1997. PMID: 9198851 Review. German.
-
[Activation of the renin-angiotensin-aldosterone system in heart failure].Ital Heart J. 2005 May;6 Suppl 1:16S-23S. Ital Heart J. 2005. PMID: 15945296 Review. Italian.
-
Diastolic heart failure.Ital Heart J. 2004 Jun;5 Suppl 6:48S-54S. Ital Heart J. 2004. PMID: 15185915 Review.
-
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31. Pharmacotherapy. 2009. PMID: 19113795 Review.
-
Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.Fiziol Cheloveka. 2005 Nov-Dec;31(6):97-105. Fiziol Cheloveka. 2005. PMID: 16366159 Review.
Cited by
-
Septal E/e' Ratio Is Associated With Cerebral White Matter Hyperintensity Progression in Young-Old Hypertensive Patients.Circ Rep. 2023 Jan 26;5(2):38-45. doi: 10.1253/circrep.CR-22-0104. eCollection 2023 Feb 10. Circ Rep. 2023. PMID: 36818523 Free PMC article.
-
The relationship between liver enzymes, prehypertension and hypertension in the Azar cohort population.BMC Cardiovasc Disord. 2024 Jun 7;24(1):294. doi: 10.1186/s12872-024-03969-x. BMC Cardiovasc Disord. 2024. PMID: 38849721 Free PMC article.
-
Metabolic syndrome, left ventricular diastolic dysfunction and heart failure with preserved ejective fraction.Front Endocrinol (Lausanne). 2025 Apr 14;16:1544908. doi: 10.3389/fendo.2025.1544908. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40297180 Free PMC article. Review.
-
Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models.Channels (Austin). 2023 Dec;17(1):2281743. doi: 10.1080/19336950.2023.2281743. Epub 2023 Nov 20. Channels (Austin). 2023. PMID: 37983306 Free PMC article. Review.
-
Role of inflammation in diabetic cardiomyopathy.Ther Adv Endocrinol Metab. 2022 Mar 15;13:20420188221083530. doi: 10.1177/20420188221083530. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 35308180 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous